Erectile Dysfunction

Detailed Overview

Penile erection is a complex neurovascular event that relies on the intact functioning of the autonomic and somatic nervous systems, arterial blood flow, and the veno-occlusive mechanism of the corpora cavernosa. ED is rarely a primary disease; it is most often a symptom of underlying systemic conditions, particularly endothelial dysfunction and cardiovascular disease. ED shares the same risk factors as coronary artery disease and often precedes clinical cardiovascular events by 3 to 5 years, acting as an early warning sign.

Epidemiology & Demographics

Highly prevalent, affecting over 150 million men worldwide. The prevalence strictly correlates with age, affecting approximately 40% of men at age 40 and up to 70% of men at age 70.

Etiological Mechanism

ED can be categorized into vasculogenic (most common, due to atherosclerosis), neurogenic (e.g., radical prostatectomy, spinal cord injury), hormonal (hypogonadism), psychogenic (performance anxiety, depression), and iatrogenic (medication-induced).

Primary Causes

Atherosclerosis and Endothelial Dysfunction

Diabetes Mellitus (neurovascular damage)

Prostate surgery or pelvic irradiation

Medications (e.g., SSRIs, Beta-blockers, Thiazides)

Testosterone Deficiency

• Diabetes Mellitus: Increases risk 3-fold due to microvascular and neuropathic complications.
• Hypertension: Alters vascular compliance and is often treated with drugs that worsen ED.
• Smoking: Induces oxidative stress and endothelial dysfunction, impairing nitric oxide release.
• Obesity and Metabolic Syndrome: Associated with insulin resistance, low testosterone, and systemic inflammation.

Normal erection requires nitric oxide (NO) release from parasympathetic nerve endings and endothelium in the corpora cavernosa. NO stimulates guanylate cyclase, converting GTP to cGMP. cGMP causes smooth muscle relaxation, allowing rapid arterial inflow into the cavernous sinusoids. The expanding sinusoids compress the subtunical venules against the tunica albuginea, creating veno-occlusion and trapping blood. In organic ED, endothelial dysfunction reduces NO bioavailability. Atherosclerotic plaques reduce arterial inflow. Structural changes (fibrosis) in the corpus cavernosum prevent adequate expansion and veno-occlusion (venous leak).

Characteristic Clinical Presentation

• Inability to achieve erection: Failure of the penis to become firm upon sexual arousal.
• Inability to maintain erection: Erection is achieved but lost before or during intercourse.
• Reduced sexual desire: Decreased libido, frequently co-occurring, especially if hypogonadism or depression is present.
• Loss of nocturnal erections: Absence of morning or night-time erections strongly suggests organic rather than psychogenic ED.

Physical Examination Signs

• Diminished peripheral pulses (e.g., dorsalis pedis) suggesting systemic atherosclerosis
• Testicular atrophy or loss of secondary sexual characteristics (suggests hypogonadism)
• Peyronie's plaques (palpable fibrotic nodules on the penile shaft)
• Abnormal bulbocavernosus reflex (indicates neurological deficit)

• Psychological Distress: Severe anxiety, depression, and loss of self-esteem.
• Relationship Conflict: Stress on intimate relationships and partner dissatisfaction.
• Infertility: Inability to perform intravaginal ejaculation.

Diagnostic Criteria & Guidelines

Diagnosis is clinical, based on patient history using standardized questionnaires like the International Index of Erectile Function (IIEF-5). Organic ED is characterized by gradual onset and loss of nocturnal erections. Psychogenic ED often has sudden onset, situational occurrences, and preserved nocturnal erections.

Differential Diagnosis

• Premature Ejaculation
• Peyronie's Disease
• Primary Hypogonadism
• Major Depressive Disorder

Laboratory Tests & Biomarkers

• Fasting Lipid Panel & HbA1c: Often abnormal, identifying underlying cardiovascular risk factors.
• Serum Total Morning Testosterone: Low (< 300 ng/dL) indicates hypogonadism. Check LH/FSH and Prolactin if low.

Imaging Modalities & Findings

• Penile Doppler Ultrasound:

• Mild
  Occasional inability to achieve/maintain erection. IIEF-5 score 17-21.
• Moderate
  Frequent inability to achieve/maintain erection. IIEF-5 score 8-16.
• Severe
  Complete inability to achieve/maintain erection. IIEF-5 score 5-7.

Second-Line & Adjunctive Therapy

Intracavernosal Injections: Alprostadil (PGE1) 10-20 mcg injected directly into the corpus cavernosum using a 29g needle. Intraurethral Suppositories (MUSE): Alprostadil 500-1000 mcg inserted into the urethra. Vacuum Erection Devices (VED).

Surgical & Procedural Management

Penile Prosthesis Implantation. Inflatable Penile Prosthesis (3-piece is the gold standard) is highly effective and offers the highest patient and partner satisfaction rates for medical-refractory ED.

Recommended Lifestyle Changes

• Weight loss and Mediterranean diet to improve endothelial function.
• Aerobic exercise for at least 150 minutes per week.
• Smoking cessation to halt progressive vascular damage.

Patient Counseling & Advice

Educate that PDE5 inhibitors are not magic pills; they require sexual stimulation to work. Explain proper timing and food interactions (especially for Sildenafil). Reassure that ED is common and highly treatable. Stress cardiovascular screening.

Follow-Up & Monitoring Schedule

Re-evaluate at 4-6 weeks after initiating PDE5 inhibitors to assess efficacy, side effects, and proper usage. Screen annually for cardiovascular disease progression.

Preventive Strategies

Maintenance of a healthy lifestyle (diet, exercise) and strict management of hypertension, hyperlipidemia, and diabetes. Avoidance of excessive alcohol and tobacco.

Highly treatable. Over 70% of men respond well to oral PDE5 inhibitors. For non-responders, injection therapies or surgical prostheses offer >90% success rates.